Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Versartis
275 Shoreline Dr., Suite 450
Redwood City, CA 94065
Phone: 650-963-8580
www.versartis.com

Versartis, Inc. is a biotechnology company developing therapeutics for the treatment of endocrine disorders. The company's lead product candidate is VRS-317, a once monthly form of human growth hormone. Versartis is pursuing the development of new therapeutic proteins utilizing the proprietary Amunix half-life extension XTEN technology. XTEN is a novel hydrophilic sequence of natural amino acids and is expressed as a fusion protein with a therapeutically active peptide or protein. New compounds developed by Versartis using the XTEN technology are expected to provide improved therapeutic outcomes such as enhanced efficacy/compliance, fewer side effects, prolonged half-life (up to monthly dosing), as well as low-cost production and enhanced stability.

Key Contact
Name
Jeffrey Cleland
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
01/15/13 $25,000,000 Series C Advent Venture Partner
Aisling Capital
Index Ventures
New Leaf Venture Partners
undisclosed
02/18/14 $55,000,000 Series E Advent Life Sciences
Aisling Capital
New Leaf Venture Partners
Sofinnova Ventures
undisclosed